About Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Jazz Pharmaceuticals Plc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments primarily in the areas of sleep medicine, neurology, and hematology. The company is dedicated to addressing significant unmet medical needs by creating therapies that improve patient outcomes and quality of life. Jazz Pharma's portfolio includes a range of pharmaceutical products designed to treat various conditions, with a particular emphasis on disorders related to sleep and central nervous system disorders. Through its research and development initiatives, the company aims to advance the scientific understanding of these conditions and contribute to the broader healthcare landscape. Read More
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong first-qu...
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 19.1% year on year ...
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) announced better-than-expected revenue in Q1 CY2026, with sales up 19.1% year on year to $1.07 billion. ...
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Tuesday after market hours. Here’s what you need to know. Jazz Pharmaceut...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
What a time it’s been for Jazz Pharmaceuticals. In the past six months alone, the company’s stock price has increased by a massive 46%, reaching $200.71 per ...
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total potential value of $7.8 billion. This massive acquisition is centered on Centessa’s lead asset, cleminorexton (formerly ORX750), a
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq: CNTA) in a blockbuster transaction valued at up to $7.8 billion. This acquisition marks a watershed moment for the treatment of sleep-wake disorders and underscores the intense [...]
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ)
jumped 13.5% in the afternoon session after the company reported better-than-expected fourth-quarter 2025 revenue and earnings.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.1% year on year to $1.20 billion. On the other hand, the company’s full-year revenue guidance of $4.38 billion at the midpoint came in 2.8% below analysts’ estimates. Its non-GAAP profit of $6.64 per share was 2.1% above analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ)
will be announcing earnings results this Tuesday after market close. Here’s what you need to know.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
